Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generex's oral insulin submitted for approval in Syria

This article was originally published in Scrip

Executive Summary

Generex Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, Generex Oral-lyn, and expects approval before the end of next year. Generex's product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel